Table 2. Frequency of osteoporosis and fractures, demographic and clinical data, RA therapy and BP pretreatment of cohort 1 and cohort 2 in RA subgroups according to disease duration.

	Disease duration ≤2 years(n=386)			Disease duration >2 years(n=700)
	Years 1996–2004cohort 1(n=92)	Years 2005–2019cohort 2(n=294)	P value*	Years 1996–2004cohort 1(n=398)	Years 2005–2019cohort 2(n=302)	P value*
Frequency of osteoporosis and fractures
Osteoporosis (%)	33.0	28.6	ns	51.6	28.2	<0.001
Peripheral fractures (%)	12.1	6.5	ns	22.8	17.5	ns
Vertebral fractures (%)	4.5	6.8	ns	12.3	6.3	0.013
Demographic data
Age (years)	58.1±15.2	62.4±12.5	ns	58.4±12.6	60.1±12.6	ns
Disease duration	0.86±0.63	0.28±1.01	<0.001	14.3±10.1	12.8±9.3	ns
BMI (kg/m2)	27.7±5.0	28.3±5.8	ns	26.4±5.0	28.2±5.4	<0.001
Women/men (%)	73.6/26.4	67.0/33.0	ns	81.7/18.3	76.6/23.4	ns
Postmenopausal women (%)	54.9	56.5	ns	63.8	56.4	ns
Disease activity/serology
ESR (mm/hour)	50±31	33±26	<0.001	33±25	28±23	0.008
CRP (mg/L)	48.8±35.2	23.5±36.8	<0.001	26.0±35.2	23.6±35.0	0.010
Seropositivity (%)	61.4	64.0	ns	73.7	74.0	ns
RA therapy and BP use
GC therapy (%)	50.5	50.9	ns	83.5	81.7	ns
Cumulative GC dose (g)	2.0±4.5	1.7±5.8	ns	18.3±20.4	23.6±32.1	<0.001
csDMARD (total) (%)	40.7	34.1	ns	94.6	91.3	ns
csDMARD without bDMARD (%)	40.6	29.7	0.019	88.4	56.3	<0.001
bDMARD use (%)	0	4.8	0.034	6.25	36.9	<0.001
BP pretreatment (%)	2	9.2	0.009	15.4	21.4	0.044

^*cComparison between cohort 1 and cohort 2 of the same subgroup according to disease duration.

bDMARDsbiologic disease-modifying antirheumatic drugsBMIbody mass indexBPbisphosphonatesCRPC reactive proteincsDMARDSconventional synthetic disease-modifying antirheumatic drugsESRerythrocyte sedimentation rateGCglucocorticoidsnsnot significantRArheumatoid arthritis